• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >UNTREATED OBSTRUCTIVE SLEEP APNEA HINDERS RESPONSE TO BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION
【24h】

UNTREATED OBSTRUCTIVE SLEEP APNEA HINDERS RESPONSE TO BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION

机译：年龄相关性黄斑变性对贝伐单抗的未治疗阻塞性睡眠呼吸暂停障碍反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose:To compare functional and anatomical responses to intravitreal bevacizumab in patients with exudative age-related macular degeneration (AMD) between two groups of patients with obstructive sleep apnea (OSA) with and without treatment with continuous positive airway pressure therapy.Methods:Patients with OSA were categorized into 2 groups: 18 untreated and 20 treated with continuous positive airway pressure therapy. All patients had exudative AMD and received treatment with intravitreal bevacizumab. Central retinal thickness was plotted against time to assess anatomical response. Logarithm of the minimum angle of resolution visual acuity changes determined functional effect. Total number of intravitreal injections administered was assessed.Results:Treated OSA group received 8 7 total injections; untreated OSA group received 16 +/- 4 injections (P < 0.05). Treated OSA group achieved statistically significant better visual acuity (logarithm of the minimum angle of resolution, 0.3 +/- 0.24, 20/40), as opposed to the untreated group (logarithm of the minimum angle of resolution, 0.7 +/- 0.41; P < 0.05). Central retinal thickness improved in the treated OSA group compared with the untreated group: 358 +/- 95 m to 254 +/- 45 m and 350 +/- 75 m to 322 +/- 105 m, respectively (P < 0.05, 20/100).Conclusion:Untreated OSA hinders the response of exudative AMD to intravitreal bevacizumab. Treatment of OSA with continuous positive airway pressure therapy yields a subsequent anatomical response and functional improvement while requiring significantly less injections. Identifying and treating underlying OSA earlier in patients with exudative AMD may yield better functional outcomes.
机译：目的：比较两组患有持续性气道正压通气治疗的和未治疗的阻塞性睡眠呼吸暂停（OSA）患者在渗出性年龄相关性黄斑变性（AMD）患者中对玻璃体内贝伐单抗的功能和解剖反应。 OSA分为2组：18例未经治疗和20例经连续气道正压通气治疗。所有患者均具有渗出性AMD，并接受玻璃体内贝伐单抗治疗。将视网膜中央厚度与时间作图，以评估解剖反应。最小分辨力视力角的对数决定了功能效果。结果：治疗的OSA组共进行了8次7次注射。未经治疗的OSA组接受了16 +/- 4次注射（P <0.05）。与未治疗组相比，经治疗的OSA组的视敏度在统计学上有显着提高（最小分辨角的对数为0.3 +/- 0.24、20 / 40），而未治疗组为最小分辨角的对数为0.7 +/- 0.41; P <0.05）。与未治疗的OSA组相比，治疗后的OSA组的中央视网膜厚度有所改善：分别为358 +/- 95 m至254 +/- 45 m和350 +/- 75 m至322 +/- 105 m（P <0.05、20 / 100）。结论：未治疗的OSA会阻碍渗出性AMD对玻璃体内贝伐单抗的反应。连续气道正压通气治疗OSA可产生后续的解剖反应和功能改善，同时所需的注射次数也明显减少。在渗出性AMD患者中及早发现和治疗潜在的OSA可能会产生更好的功能预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号